Oryzon Genomics Valuation
Is ORYZ.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ORYZ.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ORYZ.F's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ORYZ.F's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ORYZ.F?
Key metric: As ORYZ.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is ORYZ.F's PS Ratio? | |
|---|---|
| PS Ratio | 6.3x |
| Sales | US$15.83m |
| Market Cap | US$100.28m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.9x |
| Enterprise Value/EBITDA | 1183.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ORYZ.F's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 18.4x | ||
PLX Protalix BioTherapeutics | 2.7x | 58.9% | US$124.4m |
IPSC Century Therapeutics | 51.6x | 18.6% | US$138.6m |
LCTX Lineage Cell Therapeutics | 14.4x | 59.4% | US$125.4m |
CDTX Cidara Therapeutics | 4.9x | 6.6% | US$221.0m |
ORYZ.F Oryzon Genomics | 6.3x | 61.7% | US$94.9m |
Price-To-Sales vs Peers: ORYZ.F is good value based on its Price-To-Sales Ratio (6.3x) compared to the peer average (18.4x).
Price to Sales Ratio vs Industry
How does ORYZ.F's PS Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: ORYZ.F is good value based on its Price-To-Sales Ratio (6.3x) compared to the US Biotechs industry average (9.9x).
Price to Sales Ratio vs Fair Ratio
What is ORYZ.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 6.3x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ORYZ.F's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$2.01 | US$6.57 +226.8% | 66.3% | US$12.58 | US$2.41 | n/a | 3 |
| Nov ’25 | n/a | US$6.83 0% | 66.3% | US$13.08 | US$2.51 | n/a | 3 |
| Oct ’25 | n/a | US$6.94 0% | 66.3% | US$13.28 | US$2.55 | n/a | 3 |
| Sep ’25 | US$1.93 | US$7.33 +280.0% | 60.9% | US$13.29 | US$2.55 | n/a | 3 |
| Aug ’25 | n/a | US$7.22 0% | 59.2% | US$12.95 | US$2.70 | n/a | 3 |
| Jul ’25 | n/a | US$7.19 0% | 59.1% | US$12.88 | US$2.68 | n/a | 3 |
| Jun ’25 | n/a | US$7.19 0% | 59.1% | US$12.89 | US$2.69 | n/a | 3 |
| May ’25 | n/a | US$7.11 0% | 59.3% | US$12.78 | US$2.66 | n/a | 3 |
| Apr ’25 | n/a | US$7.42 0% | 55.4% | US$13.02 | US$3.25 | n/a | 3 |
| Mar ’25 | n/a | US$7.42 0% | 55.4% | US$13.02 | US$3.25 | n/a | 3 |
| Feb ’25 | n/a | US$7.43 0% | 55.4% | US$13.03 | US$3.26 | n/a | 3 |
| Jan ’25 | n/a | US$8.62 0% | 65.3% | US$16.40 | US$3.28 | n/a | 3 |
| Dec ’24 | US$1.70 | US$8.37 +392.4% | 65.3% | US$15.93 | US$3.19 | n/a | 3 |
| Nov ’24 | n/a | US$8.37 0% | 65.3% | US$15.93 | US$3.19 | n/a | 3 |
| Oct ’24 | n/a | US$9.33 0% | 59.1% | US$16.64 | US$3.33 | n/a | 3 |
| Sep ’24 | n/a | US$9.33 0% | 59.1% | US$16.64 | US$3.33 | US$1.93 | 3 |
| Aug ’24 | n/a | US$9.33 0% | 59.1% | US$16.64 | US$3.33 | n/a | 3 |
| Jul ’24 | n/a | US$12.24 0% | 30.4% | US$15.96 | US$8.51 | n/a | 2 |
| Jun ’24 | US$2.45 | US$12.24 +399.5% | 30.4% | US$15.96 | US$8.51 | n/a | 2 |
| May ’24 | n/a | US$12.24 0% | 30.4% | US$15.96 | US$8.51 | n/a | 2 |
| Apr ’24 | US$2.45 | US$12.24 +399.5% | 30.4% | US$15.96 | US$8.51 | n/a | 2 |
| Mar ’24 | n/a | US$9.36 0% | 53.6% | US$15.90 | US$3.71 | n/a | 3 |
| Feb ’24 | n/a | US$9.02 0% | 53.6% | US$15.31 | US$3.57 | n/a | 3 |
| Jan ’24 | n/a | US$9.02 0% | 53.6% | US$15.31 | US$3.57 | n/a | 3 |
| Dec ’23 | n/a | US$9.02 0% | 53.6% | US$15.31 | US$3.57 | US$1.70 | 3 |
| Nov ’23 | n/a | US$9.02 0% | 53.6% | US$15.31 | US$3.57 | n/a | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Collegium Pharmaceutical
US$1.0b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$30.71
7D
2.4%
1Y
20.0%
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$59.39
7D
7.8%
1Y
20.6%
Teva Pharmaceutical Industries
US$18.8b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$16.57
7D
-2.7%
1Y
71.0%